title: Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
abstract: BACKGROUND
  Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC.
  
  
  METHODS
  In this open-label, phase I/II clinical trial, patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer received 4 sequential intraperitoneal catumaxomab infusions: day 0: 10 μg; day 3: 10 or 20 μg; day 7: 30, 50, or 100 μg; and day 10: 50, 100, or 200 μg. Dose escalation was guided by dose-limiting toxicities.
  
  
  RESULTS
  The MTD was 10, 20, 50, and 200 μg on days 0, 3, 7, and 10, respectively. Catumaxomab had an acceptable safety profile: Most common treatment-related adverse events (at the MTD) were fever, vomiting, and abdominal pain. At final examination, 11/17 evaluable patients (65%) were progression free: 1 patient had a complete and 3 a partial response. Median overall survival from the time of diagnosis of PC was 502 days.
  
  
  CONCLUSIONS
  Intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer.
authors.affiliation: Department of Abdominal, Vascular and Transplant Surgery, Cologne Merheim Medical Center, University of Witten-Herdecke, Cologne, Germany.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Ströhlein
authors.forename: Florian
authors.initials: F
authors.lastname: Lordick
authors.forename: Dominik
authors.initials: D
authors.lastname: Rüttinger
authors.forename: Klaus-Uwe
authors.initials: KU
authors.lastname: Grützner
authors.forename: Oliver C
authors.initials: OC
authors.lastname: Schemanski
authors.forename: Michael
authors.initials: M
authors.lastname: Jäger
authors.forename: Horst
authors.initials: H
authors.lastname: Lindhofer
authors.forename: Michael
authors.initials: M
authors.lastname: Hennig
authors.forename: Karl-Walter
authors.initials: KW
authors.lastname: Jauch
authors.forename: Christian
authors.initials: C
authors.lastname: Peschel
authors.forename: Markus M
authors.initials: MM
authors.lastname: Heiss
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018033:Antibodies, Bispecific / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005260:Female; D005858:Germany; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; C522419:catumaxomab